AR118787A1 - PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES - Google Patents
PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASESInfo
- Publication number
- AR118787A1 AR118787A1 ARP190102387A ARP190102387A AR118787A1 AR 118787 A1 AR118787 A1 AR 118787A1 AR P190102387 A ARP190102387 A AR P190102387A AR P190102387 A ARP190102387 A AR P190102387A AR 118787 A1 AR118787 A1 AR 118787A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding
- binding molecules
- molecules
- diseases
- treatment
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 5
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente está dirigida a moléculas de unión a PD-L1, tales como anticuerpos monoespecíficos, y fragmentos de unión a epítopo de los mismos, que son capaces de unirse a PD-L1, y a moléculas de unión multiespecíficas (por ejemplo, anticuerpos biespecíficos, diacuerpos biespecíficos, BiTEs, moléculas de unión trivalentes, etc.) que son capaces de unirse tanto a un epítopo de PD-L1 como a un epítopo de CD137 (moléculas de unión a PD-L1 ´ CD137). La presente también se dirige a composiciones farmacéuticas que comprenden tales moléculas. La presente también incluye el uso de tales moléculas en el tratamiento de enfermedades, especialmente cáncer o una enfermedad o afección asociada o caracterizada por la presencia de un sistema inmune suprimido.The present invention is directed to PD-L1 binding molecules, such as monospecific antibodies, and epitope-binding fragments thereof, that are capable of binding to PD-L1, and to multispecific binding molecules (eg, bispecific antibodies, bispecific diabodies, BiTEs, trivalent binding molecules, etc.) that are capable of binding both an epitope of PD-L1 and an epitope of CD137 (PD-L1 ´CD137 binding molecules). The present invention is also directed to pharmaceutical compositions comprising such molecules. The present invention also includes the use of such molecules in the treatment of diseases, especially cancer or a disease or condition associated with or characterized by the presence of a suppressed immune system.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721984P | 2018-08-23 | 2018-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118787A1 true AR118787A1 (en) | 2021-11-03 |
Family
ID=80053327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102387A AR118787A1 (en) | 2018-08-23 | 2019-08-22 | PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR118787A1 (en) |
-
2019
- 2019-08-22 AR ARP190102387A patent/AR118787A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000370A (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| CO2018001485A2 (en) | Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3 | |
| CO2018005932A2 (en) | Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| ECSP20024555A (en) | SPECIFIC ANTIBODIES FOR CD47 AND PD-L1 | |
| CO2018001149A2 (en) | Monoclonal antibodies against bcma | |
| CO2018010538A2 (en) | Specific poliovirus receptor (rvp) antibodies | |
| MX374810B (en) | 4-1BB ANTI-HUMAN ANTIBODIES AND THEIR USES | |
| CU20160101A7 (en) | IMMUNOGLOBULINA WITH FAB IN TANDEM | |
| MX2019006954A (en) | COMBINATION THERAPY OF ANTI-CD20 / ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS. | |
| CL2017003195A1 (en) | Affinity-matured and humanized antibodies to fcrh5 and methods for their use. | |
| CO2017006740A2 (en) | Anti-cd79b antibodies | |
| EA201891983A8 (en) | COMBINED THERAPY BY ANTIBODIES TO CD73 | |
| MX2017006167A (en) | Glycan-interacting compounds and methods of use. | |
| CU24533B1 (en) | ANTIBODIES OR FRAGMENTS THEREOF THAT BIND THYMIC STROMAL LYMPHOPOYETIN (TSLP) AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| MX2022014914A (en) | COMPOUNDS OF INTERACTION WITH GLYCANS AND METHODS OF USE. | |
| EA201791050A1 (en) | CONJUGATES OF ANTIBODIES AND MEDICINES | |
| MX2018010733A (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore. | |
| EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| BR112016014731A2 (en) | ANTI-BAFF ANTIBODIES | |
| MX2017012802A (en) | ANTISORTILINE ANTIBODIES AND METHODS FOR USE. | |
| MX2022014695A (en) | Anti-gitr antibodies and uses thereof. | |
| CL2019002735A1 (en) | Antibodies that bind to steap-1. | |
| UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
| CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
| EA201992317A1 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSTIC OF LUNG CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |